The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and ...

Here, Michelle Tsai – chief operating officer at iOnctura – and Shane Olwill – chief development officer at Asgard ...

Onsite in Chicago at ASCO 2025, web editor Nicole Raleigh sat down with Dr Danny Nguyen, medical oncologist and haematologist ...

The Association of the British Pharmaceutical Industry (ABPI) has said that the new 10-year plan for the NHS has underplayed ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

A European pharma trade organisation has said that a new strategy launched by the EU to bolster the region's standing in life ...

Kymera is celebrating the signing of two partnerships, with Gilead taking an option on one molecular glue programme, as Sanofi buys into another ...

The transition from writing to programming regulatory submissions represents one of the most significant efficiency ...

Dizal will market sunvozertinib in the US under the Zegfrovy brand name, entering a market for EGFR inhibitors currently ...

A delay, as opposed to a firm stagnation, then, but one unfolding over several years. This applies not only to SMEs, but to ...